Karachi, September 15, 2022 (PPI-OT): AGP: Margins remain unaffected amid rising cost

AGP Limited (AGP) held its Analyst Briefing yesterday to discuss its 2QCY22 financial performance and outlook. We discuss key takeaways from the meeting. To recall, AGP posted an EPS of Rs0.84 for 2QCY22, down 58% QoQ largely due to imposition of super tax, higher S and D charges and rise in finance costs amid higher interest rates.

Some of the company’s drugs relating to treatment of stomach infections, diarrhea and allergies have witnessed a spike in demand in the aftermath of floods while plans to acquire Viatris portfolio from Pfizer are on track.

Company expects to face pressure at the gross level as impact of inflation and PKR devaluation kicks in during 2HCY22 which is expected to be partially offset by the allowed upward price revision along with anticipation of a further one-time price increase allowance by DRAP considering unprecedented inflation levels.